

DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

www.drive-ab.eu

[@DRIVE_AB](https://twitter.com/DRIVE_AB)

**Driving reinvestment in R&D for
antibiotics and advocating their
responsible use**

November 2016

PLEASE FORWARD THIS TO ANYONE WHO MAY BE INTERESTED



Don't miss a beat - follow us on Twitter at [@DRIVE_AB](https://twitter.com/DRIVE_AB).

Want to get involved? Just go to our website and click "**Stakeholder Engagement**" to find out all you need to know about getting involved with the project!

What is DRIVE-AB?


DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and is composed of **16 public and 7 private partners from 12 countries**.

DRIVE-AB is addressing the growing threat of antibiotic resistance. The development of new drugs to treat drug-resistant bacterial infections is moving slowly; we need new economic models that will **stimulate the discovery and development of new antibiotics while ensuring responsible use and access**. This is where DRIVE-AB comes in.

Six teams (work packages) are working together over this three year project (2014-2017), along with the input of a wide variety of stakeholders, to produce these models in a stepwise process and will present them to appropriate decision-makers.

To see an overview of DRIVE-AB **activities and timeline**, [click here](#).

To view the complete DRIVE-AB **information package**, please [click here](#).



Happy 2nd Birthday, DRIVE-AB!

DRIVE-AB recently celebrated its second birthday by holding a **General Assembly meeting** for all partners and participants in Oslo, Norway on 17-18 October, 2016. The event facilitated discussions on the progress so far, the challenges, and the next steps for the final remaining year of the project.

Celebrating Antibiotic Awareness Day and the first World Antibiotics Awareness Week!

The 18th of November is **European Antibiotic Awareness Day!** It's that time of year when people and organizations come together to raise awareness about the growing public health threat that is antibiotic resistance. This year, the whole world is taking part in **World Antibiotic Awareness Week**.



Here are just a few of the activities that DRIVE-AB members are involved in to support Antibiotic Awareness Week:



The British Society for Antimicrobial Chemotherapy is publishing a series of editorials in **The Guardian UK**.



Oxford Journals and the Journal of Antimicrobial Chemotherapy have put together a **list of articles that are relevant to Antibiotic Awareness Week and antibiotic resistance**.



Antibiotic Action is releasing a series of true life stories about people who have been affected by antibiotic resistance and whose lives have been changed by antibiotics.

What have we been up to this year?

DRIVE-AB has been very active in **engaging with stakeholders and initiatives from around the world, attending and organizing meetings** at the **United Nations General Assembly**, the **World Health Summit**, the **Global Health Security Agenda 3rd Annual Ministerial Meeting** and our own **DRIVE-AB high-level conference on stimulating innovation, sustainable use and global access to antibiotics**.

Please [click here](#) for a full list of DRIVE-AB meetings and events.

Recent DRIVE-AB outputs

- [Report: “DRIVE-AB Conference Report: Stimulating innovation, sustainable use and global access to antibiotics”](#)
Full conference report. September 2016.
- [Publication: “The global definition of responsible antibiotic use: The DRIVE-AB project”](#)
AMR Control 2016 article by DRIVE-AB partners V. Zanichelli, B. Huttner and S. Harbarth. 12 July 2016.
- [Policy Brief #3: “The importance of multinational coordination and increased public financing for antibiotic innovation”](#)
Developed for the [United Nations General Assembly](#) meeting on antimicrobial resistance in September 2016. Also disseminated at the [Global Health Security Agenda 3rd Annual Ministerial Meeting](#), October 2016.
- [Publication: “An assessment of the future impact of alternative technologies on antibiotics markets”](#)
Journal of Pharmaceutical Policy and Practice article by Work Package 2. 26 October 2016.

To view all DRIVE-AB outputs to date, please see our [website](#).

Project updates by each work package

For a full breakdown of the work packages and their activities, [please check out our website](#).

Responsible use of antibiotics, new and old

The team has made great progress with research activities, stakeholder involvement and external communication over the past two years. [Following robust evidence reviews and surveys](#), they have agreed on a standardized definition of “responsible antibiotic use” as well as relevant metrics and indicators. Stakeholders include members of the medical community, global public health, research and development industries, and payers and policy makers. The team has recently published an article in the Journal of Antimicrobial Chemotherapy titled, **“The global definition of responsible antibiotic use: The DRIVE-AB project”**. To read a summary of their most recent stakeholder meeting on 28 September, [please click here](#).

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [Work Package 1A’s stakeholder engagement page](#).

Setting, communicating and revising public health priorities

WP1B has successfully gathered information from [reviews and databases around the world](#) to develop simulation models that can predict transmission and spread of antibiotic-resistant bacteria globally, regionally and locally (within hospital). The models will be [available free-of-charge online](#)

and can predict spread based on modifiable variables, which can be altered by the user to enhance the accuracy of predictions that are tailored to their environment. The data that the team has generated will be used for evidence-based criteria for the World Health Organization Priority Pathogen List, which will be finalized by February 2017.

To find out more about these activities, or if you would like to provide your valuable feedback as a stakeholder, please see [Work Package 1B's stakeholder engagement page](#).

[Antibiotic Valuation](#)

The team has completed draft manuscripts on a framework for valuing antibiotics as well as lessons learned from the pre-antibiotic era and hopes to publish these soon. Stakeholder interviews are currently underway to estimate the burden of antimicrobial resistance, and the team is planning a workshop with health technology assessment (HTA) stakeholders in early 2017 to discuss the possibilities of changing the HTA process for antibiotics.

For more detailed information on the group's progress and to find out how you can get involved, please see [Work Package 1C's stakeholder engagement page](#).

[Creation and testing of new economic models](#)

The team has engaged with a variety of stakeholders, including policy- and decision-makers, pharmaceutical companies, researchers and the medical community to develop, assess and refine their shortlist of new economic models to incentivise research and development of new antibiotics while safeguarding sustainable use and equitable access. The group has published a number of [policy briefs](#) which have been disseminated at high-level global meetings, contributed to the DRIVE-AB Conference and its report, "[Stimulating innovation, sustainable use and global access to antibiotics](#)", and has recently published an article in the Journal of Pharmaceutical Policy and Practice titled, "[An assessment of the future impact of alternative technologies on antibiotics markets](#)". The team will begin writing their final report and the recommendations for implementation in the spring of 2017 along with two policy briefs which will be directed at the World Health Assembly and the G20 Presidency.

For more detailed information on the group's progress and to find out how you can get involved, please see [Work Package 2's stakeholder engagement page](#).

[Project management and governance](#)

The teams have been busy ensuring that project activities move forward according to plans and timelines. They are also ensuring that there is effective communication between work packages and between the project and relevant organisations, that DRIVE-AB is well represented in the media, and that appropriate stakeholders are being engaged to develop robust, implementable outputs.

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

[Stakeholder platform and external communication](#)

This team is currently involved in the planning of various upcoming meetings and events, such as a stakeholder meeting with small and medium sized pharmaceutical enterprises, to be held in January in London, and the final DRIVE-AB conference, which will take place in autumn 2017. The team has also updated their communications strategy for the final year of the project in response to the rapidly-changing environment of antibiotic resistance. Don't forget to see their two-page [overview of the DRIVE-AB project](#), which is available in postcard form for easy dissemination, as well as a new '[Stakeholder Engagement](#)' tab on the website to facilitate stakeholder engagement.

For more detailed information on the group's progress, please see the [DRIVE-AB website](#).

[Want to find out more?](#)

Should you wish to receive more detailed information, subscribe to the newsletter, nominate a stakeholder or update us on your activities as relevant to the project, please contact

Victoria Wells, DRIVE-AB Communications Officer.

[Edit your subscription](#) | [Unsubscribe](#)